SEC Form 8-K Summary
Filing date: January 7, 2022; signed January 13, 2022. Registrant identified in the filing: Jupiter Wellness, Inc., not BONK, Inc. The filing reports material agreements related to a proposed acquisition and financing transaction.
Business Context and Transaction
- Jupiter Wellness amended and restated its agreement to acquire approximately 94.2% of Next Frontier Pharmaceuticals, Inc. from Next Frontier Holdings, Inc. and an individual seller.
- The proposed consideration includes newly created Convertible Series B Preferred Stock and the common shares issuable upon conversion.
- Jupiter also expects to contribute certain consumer products assets to SRM Entertainment Ltd. and distribute all SRM common shares to Jupiter stockholders after closing, registration of SRM shares on a national exchange, and completion of the acquisition. The distribution is required to occur as soon as practicable and no later than 90 days after closing.
Financial Metrics, Financing, and Liquidity
- The filing does not provide revenue, earnings, margins, operating cash flow, or comparative-period financial results.
- On January 7, 2022, Jupiter funded $1.0 million to Next Frontier Pharmaceuticals under a secured promissory note with a stated principal commitment of up to $5.0 million.
- The note bears interest at 8% annually and permits principal to be borrowed, repaid, and re-borrowed at Jupiter’s discretion.
- Maturity is the earliest of six months after issuance, an event of default, or the date a new third-party lender advances funds to Next Frontier Pharmaceuticals.
- The note is secured by specified Next Frontier and Benuvia entities and is subject to an intercreditor and subordination agreement. The note constitutes additional junior liabilities.
Material Changes and Governance Arrangements
- The amended agreement changes the acquisition from an anticipated purchase of substantially all shares to a purchase of approximately 94.2% of Next Frontier Pharmaceuticals.
- Closing requires stockholder and Nasdaq-related approvals, including approval of the preferred-stock issuance, underlying common shares, charter amendments, and related transition agreements.
- The board recommended that stockholders approve the transaction proposals, which are interdependent and may be abandoned under specified termination provisions.
- Jupiter’s management team, which owns approximately 33% of outstanding common stock, entered into a stockholders agreement providing approval rights over specified major actions for 12 months after closing.
- Sellers and management agreed to vote their Jupiter shares in favor of the transactions.
- For six months after closing, sellers generally may not transfer the preferred stock or underlying common shares without required approval.
Outlook, Risks, and Unusual Items
- The acquisition, asset contribution, distribution, stock issuance, and Nasdaq listing remain subject to conditions, approvals, and other closing requirements; the filing does not state that closing has occurred.
- Existing executives are expected to transition to advisory roles for 12 months after closing. Stated signing bonuses total $755,000, and stated annualized advisory fees total $755,000, subject to the definitive agreements.
- The confidentiality agreement includes a 12-month non-solicitation period and, if the acquisition is not completed, a 12-month standstill applicable to Next Frontier Pharmaceuticals.
- The company identifies customary forward-looking statement risks, including failure to obtain approvals, failure to complete the transactions, financing and integration risks, and risks disclosed in its other SEC filings.
Investor Verification Checklist
- Verify the correct issuer: the supplied filing is for Jupiter Wellness, Inc. under ticker JUPW, not BONK, Inc.
- Review the definitive acquisition agreement for purchase consideration, ownership percentages, closing conditions, termination rights, and omitted schedules.
- Confirm stockholder and Nasdaq approvals and determine whether the preferred stock and underlying common shares were ultimately issued.
- Assess the collectability, collateral priority, maturity, and outstanding balance of the $1.0 million loan and the $5.0 million commitment.
- Verify whether the SRM asset contribution, stock registration, and distribution to Jupiter stockholders occurred.
- Review the transition advisory agreements for final compensation, termination terms, and related-party implications.